Archives
-
Ac-YVAD-CMK in Kupffer Cell Inflammation Assays
2026-08-31
Ac-YVAD-CMK helps separate caspase-1-dependent cytokine maturation from plasma-membrane repair during Kupffer cell and Listeria research. This workflow combines pharmacological inhibition, TMEM16F genetics, membrane-integrity measurements, and cytokine profiling for more interpretable pyroptosis data.
-
Stat3 in Fyn-Driven Dopaminergic Neurodegeneration
2026-08-31
A 2024 zebrafish study identifies Stat3 as a downstream effector that cooperates with NF-κB in Fyn-driven dopaminergic neuron loss and microglia activation. Its combination of cell-type-specific modeling, live imaging, transcriptomics, and pathway inhibition provides a mechanistic framework for studying neuroinflammation in Parkinson’s disease-relevant systems.
-
Spatial Lipid Mapping of POCD in Rat Hippocampus
2026-08-30
This study combines a rat cardiopulmonary bypass model, Barnes maze testing, mass spectrometry imaging, immunofluorescence, and electron microscopy to define spatial lipid disturbances associated with postoperative cognitive dysfunction. Its findings connect hippocampal CA1 lipid accumulation and altered iPLA2/SPT signaling with synaptic structural changes, while DHA and Myriocin treatment provide initial evidence that correcting these metabolic disturbances can reduce POCD-related impairment.
-
Reserpine (N1867): Practical Lab Workflow
2026-08-29
Reserpine (SKU N1867) provides a characterized natural-product reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. It is intended for research use only; its water and ethanol insolubility, potent biological activity, and limited product-specific evidence require deliberate stock preparation, vehicle controls, and assay-specific validation.
-
How GBM Apoptotic Priming Enables BH3 Mimetics
2026-08-28
Koessinger and colleagues show that glioblastoma depends on the anti-apoptotic proteins BCL-xL and MCL-1, with stem-like tumor cells displaying particularly strong apoptotic buffering. The study’s central translational insight is that sequential inhibition of these BCL-2 family proteins can convert GBM apoptotic sensitivity into robust tumor control in vivo without overt toxicity in the tested models.
-
Praeruptorin A Assay Design Guide
2026-08-28
A scenario-based guide to using Praeruptorin A (SKU N2885) in cell viability, proliferation, cytotoxicity, inflammation, and ferroptosis workflows. It addresses stock preparation, concentration selection, assay interpretation, cross-domain limitations, and practical supplier evaluation.
-
Intestinal TM6SF2 and the Gut–Liver Axis in MASH
2026-08-27
The reference study shows that intestinal epithelial TM6SF2 protects against metabolic dysfunction-associated steatohepatitis by maintaining barrier function and regulating host–microbe communication. Conditional knockout, fecal transplantation, co-housing, and pharmacological experiments connect intestinal lipid handling to pathobiont enrichment and lysophosphatidic acid signaling in the liver.
-
EZ Cap Cy5 Firefly Luciferase mRNA Lab Guide
2026-08-27
Learn how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), SKU R1010, can resolve common assay problems involving transfection variability, cellular uptake, translation, and ATP-dependent viability readouts. This scenario-based guide connects dual fluorescence–luminescence reporting with practical handling, optimization, interpretation, and vendor-selection decisions.
-
DAPT (GSI-IX) for Notch Signaling Workflows
2026-08-26
DAPT (GSI-IX) provides a practical way to test whether γ-secretase-dependent Notch activity contributes to angiogenesis, tumor biology, immune regulation, or APP processing. This workflow-focused guide connects pathway inhibition with assay design, controls, troubleshooting, and translational interpretation.
-
Firefly Luciferase mRNA as a Delivery Readout
2026-08-26
Firefly Luciferase mRNA can do more than report gene expression: it can help separate delivery, translation, and immune effects in mRNA experiments. This guide uses the R1013 design and recent nanovaccine evidence to build more informative assay workflows.
-
OMVs Enable Rapid Display of mRNA Tumor Antigens
2026-08-25
The reference study developed genetically engineered outer membrane vesicles that rapidly bind sequence-tagged mRNA antigens and promote dendritic-cell cross-presentation. This Plug-and-Display system produced strong antitumor effects in mouse models, while highlighting a delivery strategy that differs from lipid nanoparticle encapsulation for personalized mRNA vaccination.
-
Engineering Better mRNA Readouts with Firefly Luciferase
2026-08-25
A mechanistic and strategic guide to using Cap1-capped, 5-moUTP modified mRNA as a controlled reporter payload for translation studies, delivery-vector benchmarking, and translational imaging workflows.
-
Synthetic Efferocytic Microglia for Amyloid-β Clearance
2026-08-24
Shao and colleagues engineered a synthetic efferocytic receptor that redirected microglia toward amyloid-β clearance while promoting anti-inflammatory signaling in a mouse model of Alzheimer’s disease. The study combines receptor engineering with microglia-directed mRNA lipid nanoparticles, providing a framework for in situ immune-cell reprogramming rather than systemic antibody-mediated activation.
-
EZ Cap™ Cas9 mRNA for Neurodegeneration Models
2026-08-24
Build fast, transient CRISPR-Cas9 perturbation workflows for zebrafish and cell-based neurodegeneration studies with a Cap1-, 5-moUTP-modified Cas9 transcript. The workflow connects Fyn–Stat3 biology to practical functional gene studies while emphasizing dose control, RNA integrity, and phenotype-specific validation.
-
TPCA-1 in Septic AKI NF-κB Research
2026-08-23
Explore how TPCA-1, a selective IKK-2 inhibitor, can be used to interrogate the NF-κB/Apaf1/caspase-9/autophagy axis in septic acute kidney injury. This mechanistic guide translates recent renal biology into practical assay and experimental-design decisions.